RxDoctor Payments DataLook up a doctor →

Cherish Hannah, PA

Medical · Glen Burnie, MDNPI 1336809649

Payments from drug & device makers

$10,818in general payments, 2019–2025

Across 601 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Madrigal Pharmaceuticals$732
  • Bristol Myers Squibb$441
  • Sanofi$432
  • plus $4K from 29 others

What the payments were for

  • Food & beverage$10,71899%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,818 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$7,352
Medicare patients
67
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$353,589
Humira(Cf) PenAdalimumab13$85,722
CreonLipase/Protease/Amylase21$51,935
LinzessLinaclotide43$35,500
MotegrityPrucalopride Succinate19$15,696
Lubiprostone42$4,522
Esomeprazole Magnesium43$2,653
Omeprazole75$1,077
Famotidine29$593
Dicyclomine Hcl24$408
Sucralfate11$368
Pantoprazole Sodium25$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$313$353,58913 claims
AbbVieCreon, Linzess$2,582$87,43564 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,274$15,69619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.

Other medical in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →